Auditor Change

Securities and Exchange Commission ("SEC") and requested that GSK furnish the Company with a letter addressed to the SEC stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter has been filed as an exhibit to this Report. Section 9 – Financial Statements and Exhibits Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter, dated August 22, 2016, from Goldstein Schechter Koch, P.A. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. August 22, 2016 SOLITRON DEVICES, INC. /s/ Tim Eriksen Tim Eriksen Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description 16.1 Letter, dated August 22, 2016, from Goldstein Schechter Koch, P.A. 4